Loss of treatment benefit due to low compliance with bisphosphonate therapy View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2008-04

AUTHORS

F. J. A. Penning-van Beest, J. A. Erkens, M. Olson, R. M. C. Herings

ABSTRACT

Among 8,822 new female bisphosphonate users, non-compliant bisphosphonate use was associated with a 45% increased risk of osteoporotic fracture compared to compliant use (MPR >or=80%). Classifying compliance into five categories, fracture risk gradually increased with poorer compliance. These results emphasize the importance of treatment compliance in obtaining maximal treatment benefit. INTRODUCTION: Bisphosphonates are widely used to treat osteoporosis and reduce fracture risk. Low compliance is frequent and will limit treatment benefit. METHODS: New female users of alendronate or risedronate between 1999-2004, aged >or=45 years were identified from PHARMO-RLS, including drug-dispensing and hospitalization data of >or= 2 million residents of the Netherlands. Patients were followed until first hospitalisation for an osteoporotic fracture, death, or end of study period. Compliance with bisphosphonates during follow-up was measured over 90-day intervals using Medication Possession Ratio (MPR). The association between compliance and fracture risk was analyzed using time-dependent Cox-regression. RESULTS: The study cohort included 8,822 new female bisphosphonate users, contributing in total 22,484 person-years of follow-up. During follow-up, 176 osteoporotic fractures occurred (excluding the first six months). Non-compliant bisphosphonate use was associated with a 45% increased fracture risk compared to compliant use (MPR >or= 80%). Classifying compliance into five categories, fracture risk gradually increased with poorer compliance (p-value <0.05 for trend). A MPR <20% was associated with an 80% increased fracture risk compared to a MPR >or= 90%. CONCLUSIONS: These results show a statistically significant association between level of compliance with bisphosphonates and level of fracture risk, emphasizing the importance of treatment compliance in obtaining maximal treatment benefit. More... »

PAGES

511-517

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00198-007-0466-1

DOI

http://dx.doi.org/10.1007/s00198-007-0466-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1016691825

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17874028


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density Conservation Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diphosphonates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fractures, Bone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Netherlands", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis, Postmenopausal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Refusal", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Pharmo Institute", 
          "id": "https://www.grid.ac/institutes/grid.418604.f", 
          "name": [
            "PHARMO Institute, P.O.Box 85222, 3508 AE Utrecht, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Beest", 
        "givenName": "F. J. A. Penning-van", 
        "id": "sg:person.012700005011.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012700005011.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pharmo Institute", 
          "id": "https://www.grid.ac/institutes/grid.418604.f", 
          "name": [
            "PHARMO Institute, P.O.Box 85222, 3508 AE Utrecht, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Erkens", 
        "givenName": "J. A.", 
        "id": "sg:person.0611030400.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611030400.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Olson", 
        "givenName": "M.", 
        "id": "sg:person.01202722664.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202722664.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Erasmus University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5645.2", 
          "name": [
            "PHARMO Institute, P.O.Box 85222, 3508 AE Utrecht, The Netherlands", 
            "Department of Health Policy & Management, Erasmus Medical Center, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Herings", 
        "givenName": "R. M. C.", 
        "id": "sg:person.013531666034.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013531666034.64"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0140-6736(02)08657-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001520719"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archinte.165.20.2414", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002136810"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/er.2001-3002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002452297"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bone.2005.10.022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003694772"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0895-4356(95)00552-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004077108"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/030079906x132370", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004482548"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.292.11.1326", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004543412"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.288.22.2868", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011994058"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/14656566.1.2.225", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013965905"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-006-0230-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015112135", 
          "https://doi.org/10.1007/s00198-006-0230-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-006-0230-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015112135", 
          "https://doi.org/10.1007/s00198-006-0230-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-006-0085-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019542455", 
          "https://doi.org/10.1007/s00198-006-0085-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-006-0085-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019542455", 
          "https://doi.org/10.1007/s00198-006-0085-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/030079905x74862", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023303316"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/030079905x74862", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023303316"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-004-1652-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023624379", 
          "https://doi.org/10.1007/s00198-004-1652-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-004-1652-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023624379", 
          "https://doi.org/10.1007/s00198-004-1652-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/er.2001-2002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025560491"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/aje/kwg114", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026476088"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4065/81.8.1013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027632822"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.285.6.785", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030618233"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archinte.162.5.537", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030643075"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s8756-3282(02)00848-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030862543"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s8756-3282(02)00848-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030862543"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.maturitas.2004.02.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032300240"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/030079906x167615", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033621879"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clinthera.2006.01.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035112208"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archinte.1995.00430160149015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035835534"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa030897", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041371161"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/030079905x61875", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041505830"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1359/jbmr.050304", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042450609"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4065/80.7.856", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050917003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archinte.155.16.1801", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054114683"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075087728", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-04", 
    "datePublishedReg": "2008-04-01", 
    "description": "Among 8,822 new female bisphosphonate users, non-compliant bisphosphonate use was associated with a 45% increased risk of osteoporotic fracture compared to compliant use (MPR >or=80%). Classifying compliance into five categories, fracture risk gradually increased with poorer compliance. These results emphasize the importance of treatment compliance in obtaining maximal treatment benefit.\nINTRODUCTION: Bisphosphonates are widely used to treat osteoporosis and reduce fracture risk. Low compliance is frequent and will limit treatment benefit.\nMETHODS: New female users of alendronate or risedronate between 1999-2004, aged >or=45 years were identified from PHARMO-RLS, including drug-dispensing and hospitalization data of >or= 2 million residents of the Netherlands. Patients were followed until first hospitalisation for an osteoporotic fracture, death, or end of study period. Compliance with bisphosphonates during follow-up was measured over 90-day intervals using Medication Possession Ratio (MPR). The association between compliance and fracture risk was analyzed using time-dependent Cox-regression.\nRESULTS: The study cohort included 8,822 new female bisphosphonate users, contributing in total 22,484 person-years of follow-up. During follow-up, 176 osteoporotic fractures occurred (excluding the first six months). Non-compliant bisphosphonate use was associated with a 45% increased fracture risk compared to compliant use (MPR >or= 80%). Classifying compliance into five categories, fracture risk gradually increased with poorer compliance (p-value <0.05 for trend). A MPR <20% was associated with an 80% increased fracture risk compared to a MPR >or= 90%.\nCONCLUSIONS: These results show a statistically significant association between level of compliance with bisphosphonates and level of fracture risk, emphasizing the importance of treatment compliance in obtaining maximal treatment benefit.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00198-007-0466-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1100834", 
        "issn": [
          "0937-941X", 
          "1433-2965"
        ], 
        "name": "Osteoporosis International", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "Loss of treatment benefit due to low compliance with bisphosphonate therapy", 
    "pagination": "511-517", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "4f87848e1ee68d08359cf96cc1dbd0b685ed945431a6759e15d83660de70da3c"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17874028"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9100105"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00198-007-0466-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1016691825"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00198-007-0466-1", 
      "https://app.dimensions.ai/details/publication/pub.1016691825"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000373_0000000373/records_13073_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2267483/"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-007-0466-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-007-0466-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-007-0466-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-007-0466-1'


 

This table displays all metadata directly associated to this object as RDF triples.

250 TRIPLES      21 PREDICATES      74 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00198-007-0466-1 schema:about N3e3d56d8030f40858a111d0fd9f34334
2 N50d36158d2404268895c49d66fc8e7c6
3 N532ee6f47fc04efda92568a4297fd725
4 N825c443783f44de6a2b819bf0f3a8c59
5 N8791a351de0c405b99681c91f4802c81
6 N9e2d9db4995040d0ba3f21bd94e70756
7 Na5b874c310b7460fb71d5f7c3e0fab54
8 Nb725d46656c64bcbbfa16d946415ed2f
9 Nc1131bef846c4b91a94e53c3c19a6c8c
10 Nd1a8355047b44742bdc975eeaf93d93a
11 Ndf0b6806169e4bc8bf2ba8bb60018326
12 Ndf1fde2b87c6491ca43e3381878a3929
13 Ne3960430dbef445589c627d09ef9abeb
14 Nf536376326e6448b9b77f1317c6d244e
15 Nf880ea8cba9b4633ba90c348d07e73c4
16 Nfc5bcbd41a4342bcb8a88f5d8906d567
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N85590e7037c7454e9f69ddd966a328ae
20 schema:citation sg:pub.10.1007/s00198-004-1652-z
21 sg:pub.10.1007/s00198-006-0085-2
22 sg:pub.10.1007/s00198-006-0230-y
23 https://app.dimensions.ai/details/publication/pub.1075087728
24 https://doi.org/10.1001/archinte.155.16.1801
25 https://doi.org/10.1001/archinte.162.5.537
26 https://doi.org/10.1001/archinte.165.20.2414
27 https://doi.org/10.1001/archinte.1995.00430160149015
28 https://doi.org/10.1001/jama.285.6.785
29 https://doi.org/10.1001/jama.288.22.2868
30 https://doi.org/10.1001/jama.292.11.1326
31 https://doi.org/10.1016/0895-4356(95)00552-8
32 https://doi.org/10.1016/j.bone.2005.10.022
33 https://doi.org/10.1016/j.clinthera.2006.01.002
34 https://doi.org/10.1016/j.maturitas.2004.02.005
35 https://doi.org/10.1016/s0140-6736(02)08657-9
36 https://doi.org/10.1016/s8756-3282(02)00848-7
37 https://doi.org/10.1056/nejmoa030897
38 https://doi.org/10.1093/aje/kwg114
39 https://doi.org/10.1185/030079905x61875
40 https://doi.org/10.1185/030079905x74862
41 https://doi.org/10.1185/030079906x132370
42 https://doi.org/10.1185/030079906x167615
43 https://doi.org/10.1210/er.2001-2002
44 https://doi.org/10.1210/er.2001-3002
45 https://doi.org/10.1359/jbmr.050304
46 https://doi.org/10.1517/14656566.1.2.225
47 https://doi.org/10.4065/80.7.856
48 https://doi.org/10.4065/81.8.1013
49 schema:datePublished 2008-04
50 schema:datePublishedReg 2008-04-01
51 schema:description Among 8,822 new female bisphosphonate users, non-compliant bisphosphonate use was associated with a 45% increased risk of osteoporotic fracture compared to compliant use (MPR >or=80%). Classifying compliance into five categories, fracture risk gradually increased with poorer compliance. These results emphasize the importance of treatment compliance in obtaining maximal treatment benefit. INTRODUCTION: Bisphosphonates are widely used to treat osteoporosis and reduce fracture risk. Low compliance is frequent and will limit treatment benefit. METHODS: New female users of alendronate or risedronate between 1999-2004, aged >or=45 years were identified from PHARMO-RLS, including drug-dispensing and hospitalization data of >or= 2 million residents of the Netherlands. Patients were followed until first hospitalisation for an osteoporotic fracture, death, or end of study period. Compliance with bisphosphonates during follow-up was measured over 90-day intervals using Medication Possession Ratio (MPR). The association between compliance and fracture risk was analyzed using time-dependent Cox-regression. RESULTS: The study cohort included 8,822 new female bisphosphonate users, contributing in total 22,484 person-years of follow-up. During follow-up, 176 osteoporotic fractures occurred (excluding the first six months). Non-compliant bisphosphonate use was associated with a 45% increased fracture risk compared to compliant use (MPR >or= 80%). Classifying compliance into five categories, fracture risk gradually increased with poorer compliance (p-value <0.05 for trend). A MPR <20% was associated with an 80% increased fracture risk compared to a MPR >or= 90%. CONCLUSIONS: These results show a statistically significant association between level of compliance with bisphosphonates and level of fracture risk, emphasizing the importance of treatment compliance in obtaining maximal treatment benefit.
52 schema:genre research_article
53 schema:inLanguage en
54 schema:isAccessibleForFree true
55 schema:isPartOf Ncfa65f7ca224498188030b1d6c9580fb
56 Nfaf0754682314b52bd6e6bf921e0f9d7
57 sg:journal.1100834
58 schema:name Loss of treatment benefit due to low compliance with bisphosphonate therapy
59 schema:pagination 511-517
60 schema:productId N74f0f47e6bc44aa3ae629b31ae8b8565
61 N75c2f5235c06494892ebbd65431187b3
62 N98f388395f274710b621db310b21f787
63 Na1c4324a84cf420791168f63e7f040de
64 Nef6a00ad368a47e99e084cf22fc9261c
65 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016691825
66 https://doi.org/10.1007/s00198-007-0466-1
67 schema:sdDatePublished 2019-04-11T14:27
68 schema:sdLicense https://scigraph.springernature.com/explorer/license/
69 schema:sdPublisher Nb0c3a4eb9dab404db5234bba8dc24f6c
70 schema:url http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2267483/
71 sgo:license sg:explorer/license/
72 sgo:sdDataset articles
73 rdf:type schema:ScholarlyArticle
74 N394c831c0dfa415f8fa26ff169be2ce2 rdf:first sg:person.013531666034.64
75 rdf:rest rdf:nil
76 N3e3d56d8030f40858a111d0fd9f34334 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Humans
78 rdf:type schema:DefinedTerm
79 N50d36158d2404268895c49d66fc8e7c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Diphosphonates
81 rdf:type schema:DefinedTerm
82 N532ee6f47fc04efda92568a4297fd725 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Follow-Up Studies
84 rdf:type schema:DefinedTerm
85 N71079220ea5749f0bac320de53238d18 rdf:first sg:person.01202722664.01
86 rdf:rest N394c831c0dfa415f8fa26ff169be2ce2
87 N74f0f47e6bc44aa3ae629b31ae8b8565 schema:name nlm_unique_id
88 schema:value 9100105
89 rdf:type schema:PropertyValue
90 N75c2f5235c06494892ebbd65431187b3 schema:name readcube_id
91 schema:value 4f87848e1ee68d08359cf96cc1dbd0b685ed945431a6759e15d83660de70da3c
92 rdf:type schema:PropertyValue
93 N825c443783f44de6a2b819bf0f3a8c59 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Bone Density Conservation Agents
95 rdf:type schema:DefinedTerm
96 N85590e7037c7454e9f69ddd966a328ae rdf:first sg:person.012700005011.01
97 rdf:rest Nf8e8dfaf9a4b4534847dba22e90ac35a
98 N8791a351de0c405b99681c91f4802c81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Netherlands
100 rdf:type schema:DefinedTerm
101 N98f388395f274710b621db310b21f787 schema:name pubmed_id
102 schema:value 17874028
103 rdf:type schema:PropertyValue
104 N9e2d9db4995040d0ba3f21bd94e70756 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Drug Administration Schedule
106 rdf:type schema:DefinedTerm
107 Na1c4324a84cf420791168f63e7f040de schema:name doi
108 schema:value 10.1007/s00198-007-0466-1
109 rdf:type schema:PropertyValue
110 Na5b874c310b7460fb71d5f7c3e0fab54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Treatment Outcome
112 rdf:type schema:DefinedTerm
113 Nb0c3a4eb9dab404db5234bba8dc24f6c schema:name Springer Nature - SN SciGraph project
114 rdf:type schema:Organization
115 Nb725d46656c64bcbbfa16d946415ed2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Aged
117 rdf:type schema:DefinedTerm
118 Nc1131bef846c4b91a94e53c3c19a6c8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Middle Aged
120 rdf:type schema:DefinedTerm
121 Ncfa65f7ca224498188030b1d6c9580fb schema:volumeNumber 19
122 rdf:type schema:PublicationVolume
123 Nd1a8355047b44742bdc975eeaf93d93a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Risk Assessment
125 rdf:type schema:DefinedTerm
126 Ndf0b6806169e4bc8bf2ba8bb60018326 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Osteoporosis, Postmenopausal
128 rdf:type schema:DefinedTerm
129 Ndf1fde2b87c6491ca43e3381878a3929 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Bone Density
131 rdf:type schema:DefinedTerm
132 Ne3960430dbef445589c627d09ef9abeb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Treatment Refusal
134 rdf:type schema:DefinedTerm
135 Nef6a00ad368a47e99e084cf22fc9261c schema:name dimensions_id
136 schema:value pub.1016691825
137 rdf:type schema:PropertyValue
138 Nf536376326e6448b9b77f1317c6d244e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Cohort Studies
140 rdf:type schema:DefinedTerm
141 Nf880ea8cba9b4633ba90c348d07e73c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Female
143 rdf:type schema:DefinedTerm
144 Nf8e8dfaf9a4b4534847dba22e90ac35a rdf:first sg:person.0611030400.18
145 rdf:rest N71079220ea5749f0bac320de53238d18
146 Nfaf0754682314b52bd6e6bf921e0f9d7 schema:issueNumber 4
147 rdf:type schema:PublicationIssue
148 Nfc5bcbd41a4342bcb8a88f5d8906d567 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Fractures, Bone
150 rdf:type schema:DefinedTerm
151 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
152 schema:name Medical and Health Sciences
153 rdf:type schema:DefinedTerm
154 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
155 schema:name Clinical Sciences
156 rdf:type schema:DefinedTerm
157 sg:journal.1100834 schema:issn 0937-941X
158 1433-2965
159 schema:name Osteoporosis International
160 rdf:type schema:Periodical
161 sg:person.01202722664.01 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
162 schema:familyName Olson
163 schema:givenName M.
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202722664.01
165 rdf:type schema:Person
166 sg:person.012700005011.01 schema:affiliation https://www.grid.ac/institutes/grid.418604.f
167 schema:familyName Beest
168 schema:givenName F. J. A. Penning-van
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012700005011.01
170 rdf:type schema:Person
171 sg:person.013531666034.64 schema:affiliation https://www.grid.ac/institutes/grid.5645.2
172 schema:familyName Herings
173 schema:givenName R. M. C.
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013531666034.64
175 rdf:type schema:Person
176 sg:person.0611030400.18 schema:affiliation https://www.grid.ac/institutes/grid.418604.f
177 schema:familyName Erkens
178 schema:givenName J. A.
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611030400.18
180 rdf:type schema:Person
181 sg:pub.10.1007/s00198-004-1652-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1023624379
182 https://doi.org/10.1007/s00198-004-1652-z
183 rdf:type schema:CreativeWork
184 sg:pub.10.1007/s00198-006-0085-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019542455
185 https://doi.org/10.1007/s00198-006-0085-2
186 rdf:type schema:CreativeWork
187 sg:pub.10.1007/s00198-006-0230-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1015112135
188 https://doi.org/10.1007/s00198-006-0230-y
189 rdf:type schema:CreativeWork
190 https://app.dimensions.ai/details/publication/pub.1075087728 schema:CreativeWork
191 https://doi.org/10.1001/archinte.155.16.1801 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054114683
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1001/archinte.162.5.537 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030643075
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1001/archinte.165.20.2414 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002136810
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1001/archinte.1995.00430160149015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035835534
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1001/jama.285.6.785 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030618233
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1001/jama.288.22.2868 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011994058
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1001/jama.292.11.1326 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004543412
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1016/0895-4356(95)00552-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004077108
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1016/j.bone.2005.10.022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003694772
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1016/j.clinthera.2006.01.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035112208
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1016/j.maturitas.2004.02.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032300240
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1016/s0140-6736(02)08657-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001520719
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1016/s8756-3282(02)00848-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030862543
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1056/nejmoa030897 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041371161
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1093/aje/kwg114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026476088
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1185/030079905x61875 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041505830
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1185/030079905x74862 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023303316
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1185/030079906x132370 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004482548
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1185/030079906x167615 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033621879
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1210/er.2001-2002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025560491
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1210/er.2001-3002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002452297
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1359/jbmr.050304 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042450609
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1517/14656566.1.2.225 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013965905
236 rdf:type schema:CreativeWork
237 https://doi.org/10.4065/80.7.856 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050917003
238 rdf:type schema:CreativeWork
239 https://doi.org/10.4065/81.8.1013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027632822
240 rdf:type schema:CreativeWork
241 https://www.grid.ac/institutes/grid.418604.f schema:alternateName Pharmo Institute
242 schema:name PHARMO Institute, P.O.Box 85222, 3508 AE Utrecht, The Netherlands
243 rdf:type schema:Organization
244 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
245 schema:name Novartis Pharma AG, Basel, Switzerland
246 rdf:type schema:Organization
247 https://www.grid.ac/institutes/grid.5645.2 schema:alternateName Erasmus University Medical Center
248 schema:name Department of Health Policy & Management, Erasmus Medical Center, Rotterdam, The Netherlands
249 PHARMO Institute, P.O.Box 85222, 3508 AE Utrecht, The Netherlands
250 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...